In the United Kingdom, universal maternal vaccination against RSV using the prefusion F protein (RSVpreF) was introduced in late summer 2024, with start dates spanning Aug 12 in Scotland and Sep 1 in England, Wales, and Northern Ireland. The program is available year-round and free of charge to all pregnant women, with vaccination administered from 28 weeks of gestation onward. This update follows the rollout of the RSVpreF program and is contextualized by its delivery during the second season of maternal RSV vaccination. Between September and December 2024, data were gathered from mothers of infants admitted with acute lower respiratory tract infections as part of the BronchStop study to assess maternal views on RSVpreF. The report notes the timing and scope of the vaccination program and the subsequent survey period. It does not, however, provide detailed findings on maternal attitudes, uptake rates, or the influence of vaccination on perceptions of RSV risk or vaccine acceptance. Where information is incomplete in the source, uncertainty is acknowledged without speculation.
In the late summer of 2024 (from Aug 12 in Scotland, and Sept 1 in England, Wales, and Northern Ireland), the universal maternal bivalent respiratory syncytial virus (RSV) prefusion F protein (RSVpreF) vaccination for pregnant women was introduced in the UK. This vaccination is now offered throughout the year and free of charge to all pregnant women, administered from 28 weeks of gestation onwards. Following RSVpreF introduction, in September to December, 2024, we surveyed mothers of infants hospitalised with acute lower respiratory tract infections in the BronchStop study to understand their views on RSVpreF.